EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma

Maud Maillard iD, Matthieu Gracia iD, Bastien Cabarrou iD, Félicien Le Louedec iD, Christelle Moreau, Mathieu Landry iD, Aurélie Brice, Thierry Lafont, Deniz Ozdin iD, Ben Allal iD, Diego Tosi iD, Gwenaelle Gravis iD und 9 weitere

British Journal of Clinical Pharmacology · 16.11.2026

DOI: 10.1002/bcp.70918 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 16.11.2026. Verfasst von Maud Maillard und 20 weiteren Autor:innen. Beteiligte Einrichtung: Univ Toulouse, Oncopole-Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancéropole GSO, Conseil Scientifique ICR 2011, French Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Sunitinib and pazopanib are anti‐angiogenic tyrosine kinase inhibitors (TKIs) used for metastatic renal cancer, with substantial interindividual variability in drug response. This study aimed to explore factors explaining this variability.

Methods

Pharmacokinetics (PK) and pharmacogenomics (PG) data from 47 patients enrolled in the SUP‐R clinical trial (NCT02555748) were analysed retrospectively (32 treated with sunitinib, 15 with pazopanib). Plasma concentrations measured during the first two treatment cycles were analysed using a non‐linear mixed effects model. Exploratory analyses of factors influencing drug exposure, toxicity and efficacy were conducted, including a PG investigation of drug disposition, and target genes and baseline circulating microRNA levels. No correction for multiple comparisons was applied.

Results

The PK models adequately described plasma concentration over time in the cohort. Patients experiencing severe toxicity (≥ Grade 3, CTCAE) showed reduced apparent sunitinib clearance (median 24.3 L/h [11.1–45.7] vs . 32.4 L/h [16.6–90.6], p = 0.006). Responders were more exposed to sunitinib and active metabolite SU12662 (observed C trough,ss = 140.1 ng/mL [43.2–209.5] vs . 89.5 ng/mL [4.3–230.7], p = 0.036); similar trends were observed with pazopanib, though limited events (3 responders/10 evaluable) precluded definitive interpretation. Carriers of at least one variant ABCB1 c.1199G>A allele were more likely to respond to TKI treatment (odd‐ratio = 10.8, 95% confidence interval [1.7–69.9], p = 0.012).

Conclusion

This study assessed the exposure‐response relationships of both drugs and identified potential factors to consider in case of toxicity or treatment failure.

Schlagwörter

Stichwörter der Autor:innen

circulating microRNAsmetastatic renal cancerpazopanibpharmacogenomicspharmacokineticssunitinib

Autor:innen und Institutionen

  • Univ Toulouse, Oncopole-Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France.
  • Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Biostatistics & Health Data Science Unit, Toulouse, France.
  • Univ Toulouse, Inserm, CRCT, Toulouse, France.
  • Faculté de Pharmacie, University of Montréal, Montréal, Québec, Canada.
  • Institut Régional Du Cancer de Montpellier, Montpellier, France.
  • Department of Medical Oncology, Institut Paoli-Calmettes, Aix Marseille Univ, INSERM, CNRS, CRCM, Immunity and Cancer Team, Marseille, France.

ORCID-Profile: Maud Maillard, Matthieu Gracia, Bastien Cabarrou, Félicien Le Louedec, Mathieu Landry, Deniz Ozdin, Ben Allal, Diego Tosi, Gwenaelle Gravis, Guilhem Roubaud, Frédéric Thuillier, Helen Boyle, Florent Puisset, Mélanie White-Koning, Etienne Chatelut, Loïc Mourey, Fabienne Thomas

Förderung

  • Cancéropole GSO
  • Conseil Scientifique ICR 2011
  • French Ministry of Health

Zitieren

APA

Maillard, M., Gracia, M., Cabarrou, B., Le Louedec, F., Moreau, C., Landry, M., Brice, A., Lafont, T., Ozdin, D., Allal, B., Tosi, D., Gravis, G., Roubaud, G., Thuillier, F., Boyle, H., Puisset, F., White-Koning, M., Pradines, A., Chatelut, E., …, & Thomas, F. (2026). Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70918

Vancouver

Maillard M, Gracia M, Cabarrou B, Le Louedec F, Moreau C, Landry M, et al. Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70918

BibTeX
@article{Maillard2026,
  author = {Maillard, Maud and Gracia, Matthieu and Cabarrou, Bastien and Le Louedec, Félicien and Moreau, Christelle and Landry, Mathieu and Brice, Aurélie and Lafont, Thierry and Ozdin, Deniz and Allal, Ben and Tosi, Diego and Gravis, Gwenaelle and Roubaud, Guilhem and Thuillier, Frédéric and Boyle, Helen and Puisset, Florent and White-Koning, Mélanie and Pradines, Anne and Chatelut, Etienne and Mourey, Loïc and Thomas, Fabienne},
  title = {Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70918}
}
Kostenlos starten →